ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,207.84
0.39%
Dow Jones
39,311.89
0.65%
US Dollar vs MXN
16.8588
-0.36%
Brent Oil
83.49
-0.08%
Bitcoin
62,053.54
1.42%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) Noticias

TVTX Travere Therapeutics Inc

6.78
-0.04 (-0.59%)
Última actualización: 12:19:43
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Travere Therapeutics Inc TVTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.04 -0.59% 6.78 12:19:43
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.87 6.66 6.87 6.82
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/5/202415:30GLOBETravere Therapeutics to Present at Upcoming Investor..
06/5/202415:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202415:05EDGAR2Form 8-K - Current report
06/5/202415:01GLOBETravere Therapeutics Reports First Quarter 2024 Financial..
29/4/202415:30GLOBETravere Therapeutics to Report First Quarter 2024 Financial..
24/4/202406:05GLOBETravere Therapeutics and CSL Vifor Announce European..
24/4/202402:00PRNCACSL Vifor and Travere Therapeutics Announce European..
04/4/202415:30GLOBETravere Therapeutics to Present Abstracts at the Society for..
03/4/202415:30GLOBETravere Therapeutics to Present Abstracts on FILSPARI®..
13/3/202416:00GLOBETravere Therapeutics Reports Inducement Grants Under Nasdaq..
11/3/202406:05GLOBETravere Therapeutics Submits Supplemental New Drug..
26/2/202415:30GLOBETravere Therapeutics to Present at Upcoming Investor..
23/2/202415:05EDGAR2Form 8-K - Current report
23/2/202406:05GLOBETravere Therapeutics and CSL Vifor Announce Sparsentan..
23/2/202401:00PRNUSCSL Vifor and Travere Therapeutics announce sparsentan..
20/2/202407:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202415:05EDGAR2Form 8-K - Current report
15/2/202415:01GLOBETravere Therapeutics Reports Fourth Quarter and Full Year..
14/2/202413:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202415:30GLOBETravere Therapeutics to Report Fourth Quarter and Full Year..
02/2/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202420:58EDGAR2Form 144 - Report of proposed sale of securities
01/2/202420:58EDGAR2Form 144 - Report of proposed sale of securities
01/2/202420:57EDGAR2Form 144 - Report of proposed sale of securities
01/2/202415:30GLOBETravere Therapeutics to Present at the Guggenheim 6th Annual..
01/2/202411:44EDGAR2Form 144 - Report of proposed sale of securities
01/2/202408:52EDGAR2Form 144 - Report of proposed sale of securities
25/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202415:05GLOBETravere Therapeutics Announces Licensing Agreement with..
23/1/202412:17EDGAR2Form 144 - Report of proposed sale of securities
23/1/202409:51EDGAR2Form 144 - Report of proposed sale of securities
08/1/202406:07EDGAR2Form 8-K - Current report
08/1/202406:00GLOBETravere Therapeutics Provides Corporate Update and 2024..
05/1/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:30GLOBETravere Therapeutics to Present at the 42nd Annual J.P...
14/12/202306:30GLOBETravere Therapeutics Initiates Pivotal Phase 3 Clinical..
04/12/202316:14DJNTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN,..
04/12/202315:10EDGAR2Form 8-K - Current report
04/12/202315:05GLOBETravere Completes Successful pre-NDA Meeting for FILSPARI in..
21/11/202315:30GLOBETravere Therapeutics to Present at the 6th Annual Evercore..
07/11/202316:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

NASDAQ
TVTX
Travere Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados